UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 12, 2015
AMAG PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-10865 |
|
04-2742593 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
1100 Winter Street |
|
|
|
Waltham, Massachusetts |
|
02451 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(617) 498-3300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On August 12, 2015, AMAG Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the pricing of its private placement of $500 million aggregate principal amount of its senior notes due 2023 (the “Notes”). This represents a $50 million increase from the $450 million aggregate principal amount previously announced on August 5, 2015.
The Notes have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder. This Current Report on Form 8-K is neither an offer to sell nor the solicitation of an offer to buy the Notes or any other securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.
In accordance with Rule 135c under the Securities Act, a copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The Company hereby files the following exhibit:
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release dated August 12, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
AMAG PHARMACEUTICALS, INC. | ||
|
|
|
|
|
|
|
|
By: |
/s/ Frank E. Thomas |
|
|
|
Frank E. Thomas | |
|
|
|
President and Chief Operating Officer | |
|
|
|
|
|
|
|
Date: |
August 12, 2015 | |